Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol effect on lung hyperinflation in COPD
NCT00636961Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Inspiratory Capacity (IC) at Peak Time and at Isotime at Day 14. Started Feb 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00636961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636961.